Two new biomarkers useful for diagnosing inclusion myositis and autoimmune necrotizing myopathy

Partager sur

Three Belgian researchers tested the diagnostic value of two serum markers in muscle pathology: the chemokine CXCL10 and the cytokine GDF5.

  • These biomarkers were measured in 21 patients with autoimmune necrotising myopathy (ANIM), 18 with sporadic inclusion myositis (SIM), three with overlapping myositis, two with dermatomyositis and one with an anti-synthetase syndrome,
  • all were compared with 10 healthy subjects and 14 with hereditary muscle pathology,
  • CXCL10 levels were found to be almost 10 times higher in autoimmune processes than in normal subjects,
  • defining a detection threshold of 300 pg/mL for the GDF15 assay reduces the number of false negatives in NAMI.

The authors suggest incorporating these two new biomarkers into dot-myositis.

 

Retrospective Study Shows That Serum Levels of Chemokine CXCL10 and Cytokine GDF15 Support a Diagnosis of Sporadic Inclusion Body Myositis and Immune-Mediated Necrotizing Myopathy. Boel De Paepe, Ken R Bracke, Jan L De Bleecker. Brain Sci . 2023 Sep 25

On the same topic